



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61M 15/02, A61K 9/72</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/66206</b> <b>(43) International Publication Date:</b> 9 November 2000 (09.11.00)
<b>(21) International Application Number:</b> PCT/US00/11799 <b>(22) International Filing Date:</b> 2 May 2000 (02.05.00)  <b>(30) Priority Data:</b> 60/132,215      3 May 1999 (03.05.99)      US Not furnished      3 February 2000 (03.02.00)      US  <b>(71) Applicant:</b> BATTELLE MEMORIAL INSTITUTE [US/US]; 505 King Avenue, Columbus, OH 43201-2693 (US).  <b>(72) Inventors:</b> THURSTON, Rachel, M.; 7768 Heathermoon Drive, Columbus, OH 43235 (US). BROWNING, James, D.; 198 Richards Road, Columbus, OH 43214 (US). SHAH, Praful, K.; 4750 Coolbrook Drive, Columbus, OH 43026 (US). PLACKE, Michael, E.; 1473 Inglis Avenue, Columbus, OH 43212 (US).  <b>(74) Agents:</b> GOLDSTEIN, Steven, J. et al.; Frost & Jacobs LLP, 2500 PNC Center, 201 East Fifth Street, Cincinnati, OH 45202 (US).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished          upon receipt of that report.</i>
<b>(54) Title:</b> COMPOSITIONS FOR AEROSOLIZATION AND INHALATION  <b>(57) Abstract</b> <p>A composition used in combination with an electrohydrodynamic device capable of delivering an active ingredient to the aerodigestive system of the user. The composition comprises three or optionally four basic components: an active ingredient; a carrier material in which the active ingredient may be dissolved, suspended, or emulsified; an aerosol properties adjusting material which provides the composition with the physical characteristics required to create an aerosol cloud by electrostatic or electrohydrodynamic means; and optionally at least one excipient that further adjusts, preserves, stabilizes, or enhances the overall performance of the composition.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## COMPOSITIONS FOR AEROSOLIZATION AND INHALATION

5           This patent application claims the benefit of U.S. Provisional Patent Application Number 60/132,215, filed May 3, 1999, entitled "Therapeutic Formulations for Aerosolization and Inhalation," the disclosure of which is incorporated as if fully rewritten herein.

### 10                           BACKGROUND OF THE INVENTION

          This invention relates to compositions for aerosolization and delivery to the user's aerodigestive system by inhalation of the aerosolized composition, as well methods for making and using these compositions.

          Administration of active ingredients directly to the aerodigestive system  
15 (i.e., the pulmonary system and/or digestive tract) of a patient by means of an inhaled aerosol may be preferable to other methods of drug delivery in certain circumstances. Delivery of drugs or other active ingredients directly to the patient's lungs provides numerous advantages including: providing an extensive surface area for drug absorption, direct delivery of therapeutic agents to the disease site in  
20 the case of regional drug therapy, eliminating the possibility of drug degradation in the patient's intestinal tract (a risk associated with oral administration), and eliminating the need for repeated subcutaneous injections. Furthermore, delivery of drugs to the pulmonary system by means of aerosol inhalation may be used to deliver drugs systemically, as well as for targeted local drug delivery for treatment  
25 of respiratory ailments such as lung cancer or asthma.

          At the present time, inhalation therapy is a rapidly evolving technology. Numerous active ingredients are being developed with the expectation that effective delivery of and treatment with these agents will be possible by means of inhaled aerosols. Aerosolizing active ingredients requires a composition with  
30 certain characteristics and properties that make the composition compatible with the aerosolization process. The process of formulating particular active ingredients, such as drugs, with the appropriate carriers, such as organic solvents, can be particularly challenging. Therefore, there is a need for basic or general

compositions which are compatible with a variety of active ingredients, a range of suitable carriers, and appropriate aerosol generating devices.

Important considerations in administering an aerosolized active ingredient to the lungs of a patient include the characteristics of both the composition  
5 containing the active ingredient, and the aerosol cloud that will ultimately be inhaled by the patient or user. The composition must be a suitable carrier for the active ingredient, the active ingredient must be stable for a period of time in the composition, the composition must be consistently sprayable through an aerosol-generating device, and the composition must be well-tolerated by the user.  
10 Furthermore, the aerosol-generating device itself must effectively and consistently convert the formula into an aerosol cloud with certain desired properties. For example, an aerosol-generating device should not deliver a high velocity aerosol which makes it difficult for the user to inhale aerosol particles. Preferred aerosol characteristics also include an aerosol cloud composed of particles that are roughly  
15 uniform in size. An aerosol cloud composed of uniform particles of a predetermined size provides the most efficient and effective delivery of the therapeutic composition to the patient or user because the dosage that the patient receives can be more precisely controlled (i.e., uniform particle size equals more precise delivery and dosage). Therefore, for maximum effectiveness of both drug  
20 and aerosol device, consistent generation of uniformly sized aerosol particles must occur each time the composition is aerosolized with a particular device.

Aerosol devices currently used in the clinical context include metered dose inhalers, dry powder inhalers, and nebulizers. Although effective at creating  
25 aerosols, these devices typically do not permit the device user to control either the particle size of the aerosol cloud to be inhaled, or the velocity of the aerosol delivered by the device. The particle size distribution of aerosols generated with these devices is usually too broad or too varied to effectively and consistently deliver the composition to the deep lungs of the user. As a consequence, pulmonary administration of a active ingredient may be less than optimal when  
30 using metered dose inhalers, dry powder inhalers, or nebulizers due to deposition of the composition in the mouth or throat of the user or due to exhalation of the composition by the user.

U.S. Patent 4,829,996 to Noakes et al., and U.S. patent 5,707,352 to Sekins et al. both disclose formulations suitable for use with aerosol devices; however, these devices and formulas are suboptimal when compared with the performance of electrohydrodynamic (EHD) aerosol systems. EHD aerosol generators are  
5 capable of generating aerosols in which particle size, aerosol velocity, and the resultant deposition patterns can be more precisely controlled. EHD aerosol generators, therefore, are ideal devices for use with therapeutic compositions that are to be delivered to the patient's pulmonary system by inhalation. Thus, there is a need for therapeutic compositions that are compatible with both a variety of active  
10 ingredients as well as electrostatic and EHD aerosol generating devices.

### SUMMARY OF THE INVENTION

The present invention includes general compositions capable of: being aerosolized; inhaled by the user; delivering a predetermined dosage of a active  
15 ingredient to the lungs of the user; and which are optimized for use with an electrohydrodynamic aerosol generator. These compositions may contain two or more basic components which may be present in a variety of combinations, concentrations, and ratios to one another.

In a preferred embodiment of the present invention, the general  
20 composition comprises four basic, or fundamental, components. The first component is a active ingredient; examples of which include drugs, vaccines, and proteins. The second component of the therapeutic composition is a carrier material in which the active ingredient may be dissolved, suspended, or emulsified; examples of which include water or alcohol. The third component of the  
25 therapeutic composition is an aerosol properties adjusting material, which adjusts the physical properties of the liquid composition to be within ranges desired for aerosolization with an electrostatic or electrohydrodynamic device. In some embodiments of the invention the carrier material may act as the property adjusting material so as to bring the composition within the desired ranges of physical or  
30 chemical properties. In such cases no additional third basic component is required. The fourth optional component of the basic composition is at least one excipient that individually or in combination with other excipients preserves, stabilizes, or

enhances the overall performance of the therapeutic composition. Examples of suitable excipients include ionic materials, surfactants, and antimicrobial agents.

Therefore, it is an object of the present invention is to provide a general base composition that includes a suitable carrier for a variety of active ingredients,  
5 and in which the active ingredients will be stable for an extended period of time.

Another object of the present invention is to provide a base composition which is compatible with electrostatic or electrohydrodynamic aerosol generating devices.

A further object of the present invention is to provide a liquid composition  
10 with a commercially reasonable shelf-life.

Further objects, advantages, and novel aspects of this invention will become apparent from a consideration of the subsequent detailed description.

#### **DETAILED DESCRIPTION OF THE INVENTION**

15 Broadly, the present invention provides compositions, and methods for making and using compositions, which have certain preferred characteristics and properties required for generating aerosols also having particular preferred characteristics. In a preferred embodiment of the present invention, the compositions are aerosolized with an electrostatic or electrohydrodynamic (EHD)  
20 aerosol generating device. A typical embodiment of this invention includes a liquid composition having predetermined physical and chemical properties which facilitate aerosolization of the composition with an EHD aerosol device. This liquid composition typically includes three or four basic components which are (i) an active ingredient; (ii) a liquid carrier for the active ingredient; (iii) an aerosol  
25 properties adjusting material; and optionally (iv) at least one excipient. The combination of these components provides a therapeutic composition having enhanced properties for delivery to a user by means of generating an inhalable aerosol.

#### ***Electrohydrodynamic Aerosols***

The therapeutic compositions of this invention must be compatible with an aerosol-generating device so that an aerosol cloud with certain preferred properties

and characteristics is reproduced each time the device is used. Aerosols having uniformly-sized particles and uniform distribution patterns are desirable over aerosols that do not possess these characteristics because they exhibit more desirable deposition properties within the aerodigestive tract of the user (i.e., they have a higher respirable fraction). When used with compatible compositions, EHD aerosol generating devices can be adjusted to create substantially monomodal aerosols having particles more uniform in size than aerosols generated by other devices or methods.

Typical EHD devices include a spray nozzle in fluid communication with a source of liquid to be aerosolized, at least one discharge electrode, a first voltage source for maintaining the spray nozzle at a negative (or positive) potential relative to the potential of the discharge electrode, and a second voltage source for maintaining the discharge electrode at a positive (or negative) potential relative to the potential of the spray nozzle. Most EHD devices create aerosols by causing a liquid to form droplets that enter a region of high electric field strength. The electric field then imparts a net electric charge to these droplets, and this net electric charge tends to remain on the surface of the droplet. The repelling force of the charge on the surface of the droplet balances against the surface tension of the liquid in the droplet, thereby causing the droplet to form a cone-like structure known as a Taylor Cone. In the tip of this cone-like structure, the electric force exerted on the surface of the droplet overcomes the surface tension of the liquid, thereby generating a stream of liquid that disperses into a many smaller droplets of roughly the same size. These smaller droplets form a mist which constitutes the aerosol cloud that the user ultimately inhales.

#### *Physical Characteristics of Liquid Composition*

Liquid compositions that are compatible with EHD aerosol generating devices must have characteristics and properties that fall within certain parameters for the aerosol cloud to have the desired properties. In a preferred embodiment of the present invention, the most relevant physical characteristics of the composition include surface tension, electrical resistivity, and electrical permittivity (dielectric constant). Additionally, viscosity of the composition can also be of importance in

preparing liquid therapeutic compositions for use with electrostatic or EHD devices.

Surface tension is a property possessed by liquid surfaces whereby these surfaces behave as if covered by a thin elastic membrane in a state of tension.

- 5 Surface tension is a measure of the energy needed to increase the surface area of the liquid; therefore, liquids with a lower surface tension will aerosolize more easily than liquids with higher surface tension. Surface tension is measured by the force acting normally across unit length in the surface. The phenomenon of surface tension is due to unbalanced molecular cohesive forces near the surface of a liquid.
- 10 In a broad embodiment of the present invention, the surface tension of the composition is typically within the range of about 10 to 72 milliNewtons/meter. In another embodiment of the present invention, the surface tension of the composition is typically within the range of about 15 to 45 milliNewtons/meter. In a preferred embodiment of the present invention, the surface tension of the
- 15 composition is typically within the range of about 20 to 35 milliNewtons/meter.

- Electrical conductivity is the ability of a solution to transport electrical charge. The inverse of electrical conductivity is electrical resistivity. Thus, electrical resistivity is a measure of the ability of a material to resist the transport of electrical current, and is a property of a conductor, which gives the resistance in
- 20 terms of the conductor's dimensions. Liquid compositions with resistivity values of 10 to 100,000 ohm-meters can be aerosolized using EHD aerosol devices, provided that other relevant physical properties are within optimal operating parameters. Thus, in a broad embodiment of the present invention, the electrical resistivity of the composition is typically within the range of about 10 to 100,000 ohm-meters.
- 25 In another embodiment of the present invention, the electrical resistivity of the composition is typically within the range of about 50 to 10,000 ohm-meters. In a preferred embodiment of the present invention, the electrical resistivity of the liquid composition is typically within the range of about 200 to 2000 ohm-meters.

- Electrical permittivity is a measure of the polarizability of a liquid, and is
- 30 relevant in electrostatic spraying processes as it describes the increase in electrical field strength where a fluid is present. To aerosolize solvents with high permittivity (e.g., water), a higher electrical field strength (voltage) is required. The



permittivity of a liquid composition is not significantly affected by the addition of a small amount (less than 5%) of non-ionic excipients or solvents. In a broad embodiment of the present invention, the electrical permittivity of the composition is typically within the range of about 5 to 500. In another embodiment of the present invention, the electrical permittivity is typically within the range of about 10 to 150. In a preferred embodiment of the present invention, the electrical permittivity of the composition is typically within the range of about 15 to 50. Electrical permittivity is a dimensionless value denoting the ration of the electrical permittivity of a liquid or material to that of a vacuum.

Viscosity is the measure of the resistance to fluid flow; thus solutions that flow easily generally have lower viscosity. The viscosity of a liquid composition is not affected significantly by the addition of small amounts of drug to the composition. However, the addition of certain suspending agents or very high concentrations of drugs can increase the viscosity of the liquid composition. Viscosity may not be a key solvent parameter in aerosolization of the present invention, but it does affect particle size distribution. Highly viscous materials tend to form aerosols with more disperse or bimodal distributions, and with particle sizes larger than desired for respirable aerosols.

Liquid compositions having physical properties within the optimal parameters disclosed above will aerosolize when used with most EHD devices. In the present invention, controlling the voltage delivered to the system to create the region of high electric field strength also controls the particle size of the aerosol cloud generated by an EHD device. In a broad embodiment of the present invention directed toward inhalation, the size of respirable aerosol particles is typically about 0.1 to 10.0 micrometers. Aerosol particles at the lower end of this range are required for delivery of the liquid composition to the deep lung, while aerosol particles at the upper end of this range are required for delivery of the composition to the proximal respiratory tract. For deposition of the composition in the central and peripheral areas of the lung, the preferred size of the aerosol particles is about 1.0 to 6.0 micrometers.

### *Active Ingredient*

To benefit the user, the aerosolized liquid composition of the present invention contains at least one active ingredient at a concentration permitting delivery of the desired dosage to the patient. The number and types of active ingredients suitable for delivery to a patient by means of an inhaled aerosol varies widely and includes numerous options. A preferred embodiment of the present invention typically includes at least one active ingredient which may be any of the following: small molecule and synthetic drugs such as sodium cromoglycate, albuterol sulfate, and triamcinolone acetonide; chemo-therapeutic or chemopreventive agents such as paclitaxel and doxorubicin; vaccines; nucleic acids, including DNA and RNA vectors and vaccines; aptamers, proteins such as insulin; gene therapy agents for treating diseases such as cystic fibrosis; enzymes, hormones; antibodies; vitamins; peptides and polypeptides; oligonucleotides; cells; antigens; allergens; pulmonary surfactant and other surfactants (including synthetic surfactants); anti-infectious agents including antimicrobials, antibiotics, antifungals and antivirals; and pain management drugs such as narcotics.

Preferred initial concentrations of active ingredients in the composition are determined by the required effective dosage of each active ingredient, as well as the efficiency of the pulmonary delivery of the inhaled aerosol. Delivery efficiency and drug efficacy is typically impacted by the selected deposition site within the user's lung.

### *Carrier Material*

In the present invention, the composition to be aerosolized also provides a carrier in which the active ingredient may be dissolved, suspended or emulsified. A variety of solvents or emulsifying agents are suitable for this purpose. In a typical embodiment of the present invention, either water or ethanol (depending on the solubility characteristics of the active ingredient) is used as the solvent in which the active ingredient may be dissolved or suspended. In a preferred embodiment, the carrier (solvent) fraction of the composition may represent 5 to 95% of the total volume of the composition. In other embodiments, the fraction of the composition represented by the carrier varies depending on the solubility or insolubility of the

active ingredient. For example, if a active ingredient is highly soluble in the carrier (e.g. water), then the carrier fraction of the total composition may be as low as about 5% to 10%. If an active ingredient is only moderately soluble in water, a larger fraction of water may be required to completely dissolve or sufficiently suspend the active ingredient.

The pH of desired solvent, as well as the pH of the entire composition, may impact the solubility and stability of the active ingredient. Although pH requirements are likely to differ among specific compositions depending on the active ingredient being used, pH ranges useful in the present invention for the liquid carrier may be in the range of pH about 2 to 9. Preferably, a pH range of about 3 to 8 is used, and most preferably a pH range of about 5 to 8 is used.

In a preferred embodiment of the present invention, the solvents selected as carriers are chosen for use as carriers based both on compatibility with certain active ingredients and on their compatibility with EHD devices, and typically include water or ethanol. In an alternative embodiment, phospholipids or pulmonary surfactant is used as a carrier. In still another embodiment, other alcohols such as isopropanol are employed as carriers. In other embodiments of the present invention, perfluorinated compounds such as perfluorooctanol and perfluorodecalin are substituted for some or all of the water or ethanol as the carrier material. Such perfluorinated compounds are useful as alternative carriers for drugs soluble in perfluorinated carriers, micro-suspended medicaments or emulsified mixtures of such pharmaceutical products in water.

#### *Aerosol Properties Adjusting Material*

Certain physical properties of a liquid composition are critical in enhancing the effectiveness of aerosolization of the composition with an electrostatic or EHD device. Therefore, in the present invention, an aerosol properties adjusting material that provides the desired physical characteristics to the composition represents another possible fraction of the total volume of the liquid composition. In a broad embodiment of this invention, the physical properties of the liquid composition typically comprise: (i) a surface tension of about 10 to 72 milliNewtons/meter; (ii) an electrical resistivity of about 5 to 100,000 ohm-meters;

and (iii) and an electrical permittivity of about 5 to 500. In some embodiments, it may be possible to achieve a liquid composition with physical properties falling within these parameters by simply combining the active ingredient and the carrier material. However, if the combination of the active ingredient and the carrier material does not produce a liquid composition having physical properties falling within these parameters, the addition of the aerosol properties adjusting material will bring the composition within the required parameters.

In a preferred embodiment of the invention, the aerosol properties adjusting material is present as about a 5 to 90% fraction of the total volume of the composition. The volume of the aerosol properties adjusting material fraction will vary depending on the volume of the carrier that is required. For example, if the carrier represents 20% of the total volume of the composition, the aerosol properties adjusting material could represent the remaining 80% of the total volume. The 20/80 volume ratio can apply even with the active ingredient present because the active ingredient is dissolved in the carrier and/or aerosol property adjusting material. In some instances, the carrier itself may serve as the aerosol properties adjusting material.

In a preferred embodiment of the present invention, the aerosol properties adjusting material may be at least one of the following materials or their derivatives; ethanol or other alcohols; propylene glycol; polyethylene glycol; glycerol; oleic acid; medium chain triglycerides; fatty acids; soybean oil; olive oil; phospholipids, and perfluorocarbons. Combinations of these materials is advantageous in some embodiments. For example, the use of ethanol alone may create an aerosol, but the particle size of the aerosol may be below the preferred range. By combining ethanol and polyethylene glycol in a predetermined ratio to one another, the preferred particle size can be achieved. In one embodiment of the present invention, the aerosol enhancing component comprises 80% ethanol and 10% polyethylene glycol for a fraction representing 90% of the total volume of the liquid composition.

30

*Excipient*

As discussed, there are acceptable ranges of solvent parameters that permit a liquid composition to be aerosolized by the electrohydrodynamic process. Due to the characteristics of certain active ingredients (e.g., ionic, solubility limits, etc.) it may be difficult to formulate a drug at desired concentrations in an appropriate carrier solvent while remaining within the required solvent parameter values. The addition of an excipient can alter a solvent parameter and bring the composition back within the optimal ranges. Addition of an excipient is necessary only in embodiments of the present invention in which the combined active ingredient, carrier material, and aerosol properties adjusting material do not yield an aerosol with all of the desired characteristics.

Various embodiment of the present invention include at least one excipient or a combination of excipients. A broad definition of an excipient is anything in a composition other than an active ingredient. In the more narrow context of the present invention, an excipient is added for a variety of purposes including: stabilization of the liquid composition; facilitating control of aerosol particle size; increasing the solubility of the active ingredient in the composition; and lowering the surface tension of the liquid.

Once solubilized, suspended or emulsified, the active ingredient must also be stable in the carrier itself, and stable in the final composition. Stability requires that the active ingredient not lose activity prior to aerosolization (i.e. retains a reasonable shelf-life), and that the active ingredient not lose activity or degrade significantly as a result of the process of aerosolization. Furthermore, the complete composition must itself be stable over time. In various embodiments, stability issues can be addressed by the addition of a stabilizing excipient to the composition.

In a preferred embodiment of the present invention, at least one of the following excipients is added to increase physical stability of the composition: oils, glycerides, polysorbates, celluloses lecithin, polyvinyl pyrrolidone, polyethyl glycol, saccharide gums, and alginates; while ascorbic acid, citric acid, cyclodextrin, tocopherols or other antioxidants are added to increase chemical stability. In another embodiment of the present invention, chelating or complexing

agents such as citric acid, cyclodextrins, and ethylenediaminetetracetic acid may be added to stabilize drug compositions and to increase the solubility of the active ingredient in the composition.

In other embodiments, antioxidants such as ascorbic acid and ascorbic acid esters, Vitamin E, tocopherols, butylated hydroxyanisole, and butylated hydroxytoluene are added to reduce degradation of a drug composition caused by oxidation.

An excipient may also be added as a preservative to maintain the microbial integrity of the therapeutic composition. In one embodiment of the present invention, at least one of the following excipients is added to preserve compositions against microbial contamination or attack: benzalkonium chlorides, phenol, parabens, or any other acceptable antimicrobial or antifungal agent.

By further adjusting physical properties, the addition of excipients may also enhance the overall performance of the composition in terms of the quality of aerosol produced by an EHD device. In one embodiment of the present invention an ionic compound (e.g., salt) such as sodium chloride, sodium acetate, benzalkonium chloride, or lecithin, is added to further adjust electrical resistivity, thereby facilitating control of aerosol particle size.

In another embodiment of the present invention, surfactants such as lecithin, polysorbates, poloxamers, sorbitan esters, glycerides, ethoxylated alcohols, ethoxylated phenols, and ethylene oxide-propylene oxide copolymers are added to lower the surface tension of the liquid. In a preferred embodiment, non-ionic ethoxylated decyl alcohol (Desonic DA-4) having hydrophilic-lipophilic balance (HLB) of about 10.5 is added to highly aqueous compositions to enhance the dispersion characteristics of the composition. The present invention contemplates the use of both pulmonary surfactant and other natural or synthetic surfactants.

In another embodiment of the present invention, suspending agents such as celluloses, polyvinyl pyrrolidone (povidone or PVP), polyvinyl alcohol (PVA), triglycerides, ethoxylated oils, polyethyl glycol, saccharide gums, and alginates may be added to facilitate suspension of particles, or creation of an emulsion, in a liquid composition.

In still another embodiment of the present invention, adjuvants such as clove oil, citric acid, caffeine, vaccine adjuvants such as alum, polymers, macromolecules, and oligonucleotides are added to provide enhanced synergistic efficacy effect between the active ingredient and the excipient.

5        Excipients may also be added to enhance or increase the patient's ability to receive the aerosolized composition. For example, in one embodiment of the present invention, sugars, including sucrose, trehalose, and mannitol, are added either to stabilize compositions containing proteins, or to serve as sweeteners to improve the taste of the composition. In other embodiments, flavoring agents such  
10 as sugars, oils, citric acid, menthol, and camphor are added to improve the flavor of a composition.

***Examples***

The following examples of possible liquid compositions for aerosolization with an electrohydrodynamic device are meant to be illustrative of the invention,  
15 and are not meant to limit the full breadth of the invention disclosed herein.

**Aerosol Composition 1: Paclitaxel (drug).**

75 mg/ml paclitaxel in 80% ethanol; 19.8% polyethylene glycol; 0.2% citric acid.

20    **Aerosol Composition 2: Sodium Cromoglycate (drug)**

1% solution of sodium cromoglycate; 50% ethanol; 49% propylene glycol.

**Aerosol Composition 3: Albuterol Sulfate (drug)**

0.25% solution of albuterol sulfate; 70% ethanol; 29.75% water.

25

**Aerosol Composition 4: Triamcinolone Acetonide (drug)**

1% solution of triamcinolone acetonide; 70% ethanol; 29% glycerol.

While the above description discloses specific composition ingredients,  
30 ranges, and other specificities, these should not be construed as limitations on the scope of the invention, but rather as exemplification of typical embodiments thereof. Numerous other variations are possible, and it is not intended herein to

mention all of the possible equivalent forms or ramifications of the invention.

Various changes may be made to the present invention without departing from the scope of the invention.



### CLAIMS

1. A composition for creating an aerosol, comprising:

- (a) an active ingredient;
- (b) a carrier material in which said active ingredient is dissolved, emulsified, or suspended, said solution, emulsification, or suspension being  
5 within a predetermined range of properties comprising a surface tension of about 10 to 72 milliNewtons/meter, an electrical resistivity of about 10 to 100,000 ohm-meters, and an electrical permittivity of about 5 to 500; and
- (c) means for generating said aerosol, wherein said means consists of an electrostatic device or an electrohydrodynamic device.

2. A composition for creating an aerosol, comprising:

- (a) an active ingredient;
- (b) a carrier material in which said active ingredient is dissolved, emulsified, or suspended;
- 5 (c) an aerosol properties adjusting material that when added to the combination of said active ingredient and said carrier, adjusts the properties of said composition to be within a desired range, wherein said desired range of said properties comprises a surface tension of about 10 to 72 milliNewtons/meter, an electrical resistivity of about 10 to 100,000 ohm-  
10 meters, and an electrical permittivity of about 5 to 500; and
- (d) means for generating said aerosol, wherein said means consists of an electrostatic device or an electrohydrodynamic device.

3. The composition of claim 2, further comprising a ionic compound for further adjusting the electrical characteristics of said composition, wherein said ionic compound is selected from the group consisting of sodium chloride, sodium acetate, benzalkonium chloride, and lecithin.

4. The composition of claim 2, further comprising sugar for sweetening said composition.
5. The composition of claim 2, further comprising a chelating agent for stabilizing said solubilized, suspended, or emulsified active ingredient, wherein said chelating agent is selected from the group consisting of citric acid, cyclodextrins, and ethylenediaminetetracetic acid.
6. The composition of claim 2, further comprising a surfactant for further adjusting said surface tension, wherein said surfactant is selected from the group consisting of lecithin, polysorbates, poloxamers, sorbitan esters, glycerides, ethoxylated alcohols, ethoxylated phenols, ethylene oxide-propylene oxide  
5 copolymers, and pulmonary surfactant.
7. The composition of claim 6, wherein said surfactant is non-ionic ethoxylated decyl alcohol having a hydrophilic-lipophilic balance of about 10.5.
8. The composition of claim 2, further comprising a stabilizing agent for increasing the physical stability of said composition, wherein said stabilizing agent is selected from the group consisting of oils, glycerides, polysorbates, celluloses, lecithin, polyvinyl pyrrolidone, polyethyl glycol, saccharide gums, and alginates.
9. The composition of claim 2, further comprising a stabilizing agent for increasing the chemical stability of said composition, wherein said stabilizing agent is selected from the group consisting of ascorbic acid, citric acid, cyclodextrin, and tocopherols.
10. The composition of claim 2, further comprising a suspending agent for facilitating the suspension or emulsification of said active ingredient, wherein said suspending agent is selected from the group consisting of celluloses, triglycerides, ethoxylated oils, polyvinyl pyrrolidone, polyvinyl alcohol, polyethyl glycol,  
5 saccharide gums, and alginates.

11. The composition of claim 2, further comprising a preservative for maintaining the microbial integrity of said composition.
12. The composition of claim 2, further comprising an antioxidant for reducing oxidative degradation of said active ingredient in said composition, wherein said antioxidant is selected from the group consisting of ascorbic acid, tocopherols, butylated hydroxyanisole, and butylated hydroxytoluene.
13. The composition of claim 2, further comprising an adjuvant for providing a synergistic effect between said active ingredient and the other components in said composition, wherein said adjuvant is selected from the group consisting of clove oil, citric acid, alum, caffeine, vaccine adjuvants, polymers, macromolecules, and  
5 oligonucleotides.
14. The composition of claim 2, further comprising a flavoring agent for improving the taste of said composition, wherein said flavoring agent is selected from the group consisting of sugars, oils, citric acid, menthol, and camphor.
15. The composition of claim 2, wherein said surface tension of said composition is about 15 to 45 milliNewtons/meter, said electrical resistivity of said composition is about 50 to 10,000 ohm-meters, and said electrical permittivity of said composition is about 10 to 150.
16. The composition of claim 2, wherein said surface tension of said composition is about 20 to 35 milliNewtons/meter, said electrical resistivity of said composition is about 200 to 2000 ohm-meters, and said electrical permittivity of said composition is about 15 to 50.
17. The composition of claim 2, wherein said aerosol created by said electrohydrodynamic means has a substantially uniform particle size of about 0.1 to 10  $\mu\text{m}$ .

18. The composition of claim 2, wherein said active ingredient is selected from the group consisting of drugs, chemotherapeutic ingredients, chemopreventive agents, vaccines, nucleic acids, aptamers, proteins, gene therapy agents, enzymes, hormones, antibodies, vitamins, peptides, polypeptides, oligonucleotides, cells,  
5 antigens, allergens, natural surfactants, and synthetic surfactants.

19. The composition of claim 2, wherein said carrier material is a solvent selected from the group consisting of water, alcohols, phospholipids, pulmonary surfactant, and perfluorinated compounds.

20. The composition of claim 2, wherein said aerosol properties adjusting material is a solvent selected from the group consisting of ethanol, propylene glycol, polyethylene glycol, glycerol, oleic acid, medium chain triglycerides, fatty acids, soybean oil, olive oil, phospholipids, and perfluorocarbons.

21. A method of making and aerosolizing a composition, comprising:

- (a) combining an active ingredient and a carrier material to form a solution, suspension, or emulsification;
- (b) combining said solution, suspension, or emulsification with an aerosol  
5 properties adjusting material to create a composition with a surface tension of about 10 to 72 milliNewtons/meter, electrical resistivity of about 5 to 100,000 ohm-meters, and electrical permittivity of about 5 to 500;
- (c) placing said composition in an aerosol generating device; and
- (d) generating an aerosol by electrohydrodynamic means.

22. An aerosol generating device, comprising:

- (a) a spray nozzle maintained in fluid communication with a source fluid to be aerosolized,
- (b) a fluid to be aerosolized in said source of fluid, wherein said fluid is a  
5 composition comprising a active ingredient solubilized, suspended, or emulsified in a carrier material; and an aerosol properties adjusting material for adjusting the physical properties of said composition to be within a

desired range comprising a surface tension of about 10 to 72  
milliNewtons/meter, an electrical resistivity of about 5 to 100,000 ohm-  
10      meters, and an electrical permittivity of about 5 to 500; and  
(c) electrohydrodynamic means for generating said aerosol, wherein said  
electrohydrodynamic means comprises at least one discharge electrode  
located near said spray nozzle; a first voltage source maintaining said spray  
nozzle at a negative potential relative to the potential of said discharge  
15      electrode; and a second voltage source for maintaining said discharge  
electrode at a positive potential relative to the potential of said spray  
nozzle.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
9 November 2000 (09.11.2000)

PCT

(10) International Publication Number  
**WO 00/66206 A3**

- (51) International Patent Classification<sup>7</sup>: **A61M 15/02, A61K 9/72**
- (21) International Application Number: **PCT/US00/11799**
- (22) International Filing Date: **2 May 2000 (02.05.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
60/132,215 3 May 1999 (03.05.1999) US  
Not furnished 3 February 2000 (03.02.2000) US
- (71) Applicant: **BATTELLE MEMORIAL INSTITUTE**  
[US/US]; 505 KinG Avenue, Columbus, OH 43201-2693 (US).
- (72) Inventors: **THURSTON, Rachel, M.**; 7768 Heathermoon Drive, Columbus, OH 43235 (US). **BROWNING, James, D.**; 198 Richards Road, Columbus, OH 43214 (US). **SHAH, Praful, K.**; 4750 Coolbrook Drive, Columbus, OH 43026 (US). **PLACKE, Michael, E.**; 1473 Inglis Avenue, Columbus, OH 43212 (US).
- (74) Agents: **GOLDSTEIN, Steven, J. et al.**; Frost & Jacobs LLP, 2500 PNC Center, 201 East Fifth Street, Cincinnati, OH 45202 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— *With international search report.*
- (88) Date of publication of the international search report:  
**8 February 2001**
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 00/66206 A3

(54) Title: **COMPOSITIONS FOR AEROSOLIZATION AND INHALATION**

(57) Abstract: A composition used in combination with an electrohydrodynamic device capable of delivering an active ingredient to the aerodigestive system of the user. The composition comprises three or optionally four basic components: an active ingredient; a carrier material in which the active ingredient may be dissolved, suspended, or emulsified; an aerosol properties adjusting material which provides the composition with the physical characteristics required to create an aerosol cloud by electrostatic or electrohydrodynamic means; and optionally at least one excipient that further adjusts, preserves, stabilizes, or enhances the overall performance of the composition.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/11799

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61M15/02 A61K9/72

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M A61K B05B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 234 842 A (IMPERIAL CHEMICAL INDUSTRIES PLC,UK) 2 September 1987 (1987-09-02) claims 1-3,7 page 7, line 32 -page 8, line 18 page 14, line 27 -page 16, line 6 ---	1,2,6, 15,17-22
X	WO 95 26235 A (ELECTROSOLS LTD.,UK) 5 October 1995 (1995-10-05)  claims 1,5-7 page 2, line 19 -page 3, line 5 page 3, line 21 - line 33 page 5, line 10 - line 23 ---  -/-	1,2,15, 17,18, 21,22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

31 October 2000

Date of mailing of the international search report

07/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

# INTERNATIONAL SEARCH REPORT

Int. J. Application No  
PCT/US 00/11799

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	<p>WO 99 49981 A (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,FR) 7 October 1999 (1999-10-07) claims 1-3,11-15 page 15, line 16 - line 24 page 16, line 7 - line 8 page 20, line 15 -page 21, line 5 page 24, line 3 - line 5</p>	1-3,6, 15,17-22
X,P	<p>WO 99 42153 A (BESPAK PLC,UK) 26 August 1999 (1999-08-26) claims 1,9,11 page 4, line 25 - line 35</p>	1,2,15, 17-22
E	<p>WO 00 38770 A (BATTELLE MEMORIAL INSTITUTE,U.S.A.) 6 July 2000 (2000-07-06) claims 1,4,5,7,11,21,22,27,28,39,44,45,48,50-52 page 1, line 6 - line 12 page 4, line 10 page 5, line 18 - line 21 page 7, line 22 -page 8, line 4 page 15, line 1 - line 23 page 27, line 5 - line 6</p>	1,2,15, 17-22
E	<p>WO 00 35524 A (ELECTROSOLS LTD.,UK) 22 June 2000 (2000-06-22) claims 1,2,20,22,26,34,40-44,46-56 page 3, line 10 - line 18 page 4, line 5 - line 9 page 4, line 16 -page 5, line 7 page 24, line 12 - line 17 page 42, line 17 -page 43, line 11 page 43, line 24 - line 27 page 44, line 16 - line 21 page 48, line 1 - line 3 tables 1,2</p>	1,2,8, 10,17-22



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/11799

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 234842 A	02-09-1987	AT 56156 T AU 582949 B AU 6906187 A AU 594429 B AU 6906287 A CA 1275883 A DE 3764662 D DK 82587 A,B, EP 0234841 A FI 870639 A,B, FI 870640 A GR 3000843 T IE 59596 B IL 81572 A JP 2109019 C JP 8024714 B JP 62197071 A JP 62254830 A NO 870658 A,B, NO 870660 A NZ 219305 A NZ 219306 A PT 84320 A,B US 4829996 A US 4795330 A ZA 8701146 A ZA 8701147 A	15-09-1990 13-04-1989 27-08-1987 08-03-1990 27-08-1987 06-11-1990 11-10-1990 22-08-1987 02-09-1987 22-08-1987 22-08-1987 15-11-1991 09-03-1994 15-01-1992 21-11-1996 13-03-1996 31-08-1987 06-11-1987 24-08-1987 24-08-1987 26-02-1990 26-02-1990 01-03-1987 16-05-1989 03-01-1989 28-10-1987 25-11-1987
WO 9526235 A	05-10-1995	DE 69510046 D DE 69510046 T EP 0752918 A JP 9510653 T US 5813614 A	08-07-1999 23-09-1999 15-01-1997 28-10-1997 29-09-1998
WO 9949981 A	07-10-1999	FR 2776538 A AU 2940599 A	01-10-1999 18-10-1999
WO 9942153 A	26-08-1999	GB 2334461 A AU 1163999 A	25-08-1999 06-09-1999
WO 0038770 A	06-07-2000	AU 2592900 A	31-07-2000
WO 0035524 A	22-06-2000	GB 2345010 A AU 1872500 A	28-06-2000 03-07-2000